Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.

Immune-Mediated Damage

In most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal from triggering proper muscle contraction. At the same time, they activate complement proteins, which damage the membrane and destroy receptor sites. Over time, the once-folded muscle end plate becomes flattened, and the number of working receptors falls by nearly 90%. As a result, each nerve impulse produces a smaller muscle response, and repeated use quickly leads to fatigue—a hallmark of Myasthenia Gravis.

Variations in Antibody Targets

Not all patients have antibodies against acetylcholine receptors. Some develop antibodies directed at muscle-specific kinase (MuSK) or lipoprotein-related protein 4 (LRP4). These molecules help cluster and stabilize acetylcholine receptors. When attacked, the receptors cannot organize correctly, further disrupting nerve–muscle communication. Patients with these antibodies often experience prominent bulbar weakness, which can make swallowing and speech difficult.

Role of the Thymus Gland

The thymus gland, which plays a important role in regulating the development of immune cells, also contributes to disease progression. In many patients, it becomes enlarged or contains a thymoma, a benign tumor. Abnormal thymic tissue can produce immune cells that mistakenly recognize acetylcholine receptor proteins as foreign. This faulty training of immune cells sustains the production of harmful antibodies. Due to this connection, removing the thymus often reduces symptoms or induces remission, especially in cases of generalized cases.